Novo Nordisk Pharmatech

Activities: Ingredients Research & Development

Trending Articles

  1. Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research...
  2. Manufacturing Chemist Stand Side with Piramal Pharma Solutions We discover what exhibitors at CPHI 2025 are showcasing LIVE!
  3. SGS achieves breakthrough in infectious disease research with launch of novel RSV A-strain Derived from a 2015 circulating strain, SGS's novel RSV-A challenge agent offers a closer match to circulating RSV viruses than strains currently used in clinical research
  4. One in four European pharma companies at risk of regulatory breaches according to NSF research The independent survey exposed significant gaps in quality systems, supply chain oversight and data integration, just as EU GMP regulations continue to tighten
  5. IWK introduces machine to produce 100% cardboard blister packaging CABLIblue 870 features innovative “card-to-card” technology for recyclable, fiber-based blisters

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

Related Content

Media

Alzheimer's Association comments on failed Novo Nordisk GLP-1 trial

The company said the results from the evoke study, which tested an oral semaglutide pill for early-stage symptomatic Alzheimer's disease, were "not what we had hoped for"
Research & Development

Novo Nordisk’s oral semaglutide fails to slow Alzheimer’s progression in global Phase III trials

The studies showed no statistically significant benefit on disease progression despite biomarker improvements, leading to a sharp drop in the company's share price
Finance

Pfizer clinches $10bn deal to acquire weight-loss biotech Metsera after bidding war with Novo Nordisk

Metsera says that it has opted for Pfizer's revised deal after antitrust concerns surrounding rival Novo's bid for the biotech
Research & Development

Novo Nordisk's Wegovy results in patients hitting key BMI and waist size targets

New STEP UP trial data show that semaglutide enables people with obesity to achieve BMI and waist-to-height ratio targets linked to lower cardiovascular risk, alongside significant weight loss
Finance

Pfizer denied restraining order on rival Novo Nordisk in GLP-1 bidding war

The Delaware Chancery Judge rejected Pfizer's request for a temporary restraining order, arguing that the company's objections to Novo's proposed deal weren't a legitimate reason for stopping the competitor's offer
Finance

Metsera declares $10bn Novo deal "superior" after Pfizer files second lawsuit in GLP-1 row

Metsera has said Novo Nordisk’s revised offer is a “superior proposal” to Pfizer’s, escalating a high-stakes legal and acquisition battle and where Pfizer has filed a second lawsuit accusing Novo of anticompetitive behaviour and Metsera of collusion
Finance

Pfizer sues Metsera and Novo Nordisk over alleged breach of merger agreement

Pfizer has filed a lawsuit against Metsera, its Board of Directors and Novo Nordisk, alleging breach of contract, fiduciary duty and interference following Metsera’s decision to pursue a rival offer that Pfizer claims is “illegal”
Subscribe now